Any suspected adverse incident can be reported to the Canadian Adverse Drug Reaction Monitoring Program at:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
Address Locator: 0701C
OTTAWA, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
Toll free for consumers and health professionals:
Tel: 866 234-2345, Fax: 866 678-6789
The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.
The IWK Health Centre will request a report from Health Canada on any adverse reactions within Canada during the previous RSV season and review this information with the palivizumab working group annually.
Dalhousie University Health Law and Policy Seminar Series - Guaranteed Income and Health | November 2, 2018
Dalhousie University Health Law and Policy Seminar Series - Of Bricks and Blood: Institutional Conscience Objections to MAID and Abortion | November 23, 2018
Dalhousie University Health Law and Policy Seminar Series - Cannabis Legislation: Past, Present and Future | January 18, 2019